专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1998006823A2 CYTOKINE-FREE CULTURE OF DENDRITIC CELLS 审中-公开
标题翻译：小细胞细胞无细胞无血清培养
公开(公告)号：WO1998006823A2
公开(公告)日：1998-02-19
申请号：PCT/US1997013759
申请日：1997-08-13
申请人： BAXTER INTERNATIONAL INC.
发明人： BAXTER INTERNATIONAL INC. , VACHULA, Mona , VAN EPPS, Dennis, E. , ALZONA, Mortimer, T. , AONO, Frederick, M.
IPC分类号： C12N05/06
CPC分类号： C12N5/0636 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , C12N5/0639 , C12N2500/05 , C12N2500/14 , C12N2500/36 , C12N2500/38 , C12N2501/01 , C12N2501/02 , C12N2501/125 , C12N2501/22 , C12N2501/25 , C12N2501/515
摘要： A method for producing human dendritic cells for therapeutic purposes which allows culture-deriving dendritic cells using no cytokines, or reduced cytokines. The method involves culturing mononuclear cells from blood or bone marrow in a medium containing at least one agent such as a calcium ionophore, e.g. A23187, theophylline, protaglandin E1, dibutyryl cyclic AMP, Vitamin D3, Vitamin E, retinoic acid, or a fatty acid. The culture is maintained for a sufficient time, typically 4 - 14 days, to produce a culture enriched for dendritic cells, as evidenced by at least about 2.5 % of total cells exhibiting dendritic cell processes, or a dendritic cell antigen such as CD80, CD86, or CD1a. Also provided is a method to produce antigen-specific human T-cells by pulsing the dendritic cells obtained by the method of the invention with an antigen such as a viral, tumor, bacterial, or cell surface antigen, and then co-culturing T-cells with the antigen-pulsed dendritic cells. Useful for treatment of viral or bacterial infections, useful as a cancer vaccine, useful to induce tolerance of allo- or xeno-graft.
摘要翻译：本发明涉及一种生产用于治疗目的从培养物，而不细胞因子或具有很少的细胞因子的人树突状细胞的方法。所述方法包括在含有至少一种剂的培养基中培养的血液或骨髓单核细胞，例如：钙离子载体（例如，A23187），茶碱，前列腺素E1，二丁酰基环AMP ，维生素D3，维生素E，视黄酸或脂肪酸。将培养物维持足够长的时间，例如，4至14天，为生产具有的树突状细胞过程中总细胞的树突状细胞中富集至少2.5％，或细胞抗原树突如CD80，CD86或CD1a。本发明还涉及一种方法，用于生产抗原，其包括使用病毒抗原，细菌或肿瘤或细胞表面脉动通过上述方法获得的树突状细胞的特异性的人T细胞然后共同培养T细胞和抗原性冲动树突状细胞。由此获得的树突状细胞是病毒或细菌感染的治疗中是有用的，作为针对癌症的疫苗或用于感应耐受性异体或异种移植。

2. 发明申请

WO1998006826A1 DENDRITIC CELLS PRODUCED IN SERUM-FREE CULTURE 审中-公开
标题翻译：在无血清培养物中生产的细胞
公开(公告)号：WO1998006826A1
公开(公告)日：1998-02-19
申请号：PCT/US1997014383
申请日：1997-08-13
申请人： BAXTER INTERNATIONAL INC.
发明人： BAXTER INTERNATIONAL INC. , VACHULA, Mona , ALZONA, Mortimer, T. , AONO, Frederick, M. , KOWALKOWSKI, Kenneth, L. , SMITH, Stephen, L. , UNVERZAGT, Kristen, L. , VAN EPPS, Dennis, E.
IPC分类号： C12N05/08
CPC分类号： C12N5/0639 , A61K38/00 , A61K2039/5154 , A61K2039/5158 , C12N2500/05 , C12N2500/14 , C12N2500/36 , C12N2500/38 , C12N2500/90 , C12N2501/01 , C12N2501/02 , C12N2501/125 , C12N2501/22 , C12N2501/25 , C12N2501/515
摘要： A method for producing human dendritic cells (DC) for therapeutic purposes using serum-free, animal protein-free medium. The method involves culturing mononuclear cells from peripheral or umbilical cord blood or bone marrow of an individual human donor in a culture container having at least one inner surface of polystyrene in the above described medium containing at least one hematopoietic growth factor, and maintaining the culture to produce a culture enriched for DC. The DC enrichment is evidenced by at least about 10% of the total cells in the culture exhibiting DC processes, or at least 2.5 % of the total cells expressing at least one DC antigen such as CD80, CD86, or CD1a. The culture method is preferably carried out in a gas-permeable container in a closed fluid path system. The DC so produced can be pulsed with an antigen such as a viral, bacterial, tumor, or cell surface antigen, and the resulting primed dendritic cells can be co-cultured with T cells to produce antigen-specific human T-cells for therapeutic use. Useful for treatment of viral or bacterial infections, useful as a cancer vaccine, useful to induce tolerance when transplant of allo- or xeno-graft cells or organ is intended.
摘要翻译：用于使用无血清，无动物蛋白质的培养基用于治疗目的的人树突状细胞（DC）的制备方法。该方法包括在含有至少一种造血生长因子的上述培养基中具有聚苯乙烯的至少一个内表面的培养容器中培养单个人供体的外周或脐带血或骨髓的单核细胞，并将培养物保持生产富含DC的培养基。 DC富集由显示DC过程的培养物中的总细胞的至少约10％或表达至少一种DC抗原如CD80，CD86或CD1a的总细胞的至少2.5％来证明。培养方法优选在封闭流体路径系统中的透气性容器中进行。如此产生的DC可用诸如病毒，细菌，肿瘤或细胞表面抗原的抗原脉冲，并且所得引发的树突状细胞可与T细胞共培养以产生用于治疗用途的抗原特异性人T细胞。用于治疗病毒或细菌感染，可用作癌症疫苗，用于诱导同种异体移植或异种移植细胞或器官移植时的耐受性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式